Agranulocytosis from Outpatient Antimicrobial Treatment with Ceftriaxone: A Case Report



 

Yevgeniy Genchanok, MD1; Seda S Tolu, MD1; Heidy Wang2;
Shitij Arora, MD, FACP1

Perm J 2019;23:18-190 [Full Citation]

https://doi.org/10.7812/TPP/18-190
E-pub: 06/21/2019

ABSTRACT

Introduction: Agranulocytosis from antimicrobial therapy with ceftriaxone is rare. We report a case of agranulocytosis resulting from ceftriaxone noted more than 3 weeks into therapy.
Case Presentation: A 72-year-old woman who was started on ceftriaxone for septic arthritis of the left knee 3 weeks before presentation was admitted to the hospital after being found to be neutropenic on outpatient laboratory analysis. Her absolute neutrophil count on admission was 0/μL. The cause of the agranulocytosis was suspected to be ceftriaxone. The drug was stopped, and she was started on granulocyte colony-stimulating factor with gradual resolution of the neutropenia.
Discussion: Serious adverse effects of ceftriaxone therapy, such as agranulocytosis, must be monitored for, especially in patients who are receiving prolonged therapy or high doses. Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and granulocyte colony-stimulating factor should be administered with daily monitoring of the absolute neutrophil count.

INTRODUCTION      

Ceftriaxone is the most commonly used agent in outpatient parenteral antimicrobial therapy.1 It has a half-life that permits for daily dosing, thus making it a preferred agent for outpatient use. It is generally safe and well tolerated, with data showing that ceftriaxone-induced leukopenia occurs in 0.09% of the courses administered.1 We report a rare case of agranulocytosis resulting from ceftriaxone noted more than 3 weeks into therapy.

CASE PRESENTATION

Presenting Concerns

A 72-year-old woman with bilateral total knee arthroplasties presented to the Emergency Department after being found to be neutropenic on outpatient laboratory analysis. The patient had been admitted 1 month earlier because of pain and swelling in her left knee and was found to have septic arthritis of the joint. She underwent irrigation and débridement with revision of the polyethylene insert. Wound cultures yielded methicillin-sensitive Staphylococcus aureus. She was discharged on a regimen of ceftriaxone, 2 g daily, via a peripheral indwelling catheter. Her absolute neutrophil count (ANC) several days before discharge, and 1 day before starting ceftriaxone treatment, was 7221/µL. She continued receiving ceftriaxone for the next 3 weeks and was then found to have an ANC of 165/µL on outpatient bloodwork.

Her symptoms on presentation were pain in the left knee, dysgeusia, and diarrhea. Physical examination findings were unremarkable. A complete blood cell count showed white blood cells of 900/µL and an ANC of 0/µL. A peripheral blood smear showed no neutrophils or blast cells, normocytic red blood cells with mild anisocytosis and no target cells or schistocytes, and a normal platelet count without clumps. Results of an infectious disease workup, including blood cultures, urine culture, and chest x-ray film, were normal. Stool samples were negative for Clostridium difficile toxin, Giardia and Cryptosporidium organisms, and ova and parasites. Erythrocyte sedimentation rate was 84 mm/h, and C-reactive protein was 1.7 mg/dL. Hepatitis B surface antigen was negative, hepatitis C antibody was negative, and HIV antigen/antibody was negative. Antinuclear antibody titer was less than 40. Folate and vitamin B12 levels were normal. Thus, infectious, rheumatologic, and nutritional deficiency causes of neutropenia were ruled out. Results of a radiograph of the left knee noted only mild soft-tissue edema.

Therapeutic Intervention and Treatment

The cause of the agranulocytosis was suspected to be drug induced from ceftriaxone, with an adverse drug reaction probability (Naranjo) score of “probable.”2 Treatment with the medication was stopped, and the patient was started on an oral regimen of levofloxacin, 500 mg/d, and rifampin, 600 mg/d, to treat her prosthetic joint infection. In addition, treatment with filgrastim, a granulocyte colony-stimulating factor (G-CSF), was started, initially with 300 µg subcutaneously nightly.

Follow-up and Outcomes

Because the patient’s ANC remained below 100/µL after 2 doses, the G-CSF dose was increased to 480 µg. She received an additional 2 doses at this strength, and her ANC increased to 4131/µL.

The patient was subsequently discharged home, with outpatient follow-up recommended. Table 1 presents a timeline of the case.

DISCUSSION

Agranulocytosis, classically defined as a neutrophil count below 0.5 × 109/L, historically carried a mortality rate of 10% to 16%.3 Although the mortality rate has improved to 5%, the condition is still considered life-threatening and is most dangerous in patients older than age 65 years and in those with renal failure, bacteremia, or shock at the time of diagnosis.3

A previously published review of case reports from 1966 to 2006 involving 980 patients with possible drug-induced agranulocytosis identified only 6 cases in which there was a probable relationship between the agranulocytosis and ceftriaxone.4 In addition, a 2015 case report and literature review identified 13 published cases with a probable relationship between ceftriaxone and agranulocytosis.5 Data from clinical trials show that neutropenia from ceftriaxone occurred in 3% of patients, but only in those receiving 2 g for 4 weeks.6 This timeline is consistent with that of our patient, who presented with neutropenia after 25 days of 2 g of daily ceftriaxone therapy, and is similar to other reported cases.5,7 Thus, it appears that higher doses and/or prolonged treatment with ceftriaxone is a risk factor for the development of agranulocytosis.

The management and treatment of drug-induced agranulocytosis begins with identification and cessation of the offending agent. If the patient is febrile, an infectious disease workup should be performed and broad-spectrum antibiotics should be started. A bone marrow biopsy was not performed in this case; however, performing one may be essential in cases where other cell lines are affected to rule out an underlying disease process.3 A bone marrow biopsy may also help predict when to expect recovery of the neutrophil count. If there is lack of myeloid precursors, recovery is unlikely before 14 days, and if there is maturation arrest, recovery is likely within 2 to 7 days.3 Although neutrophil counts should improve once administration of the offending agent is stopped, G-CSF can be administered to decrease the time to resolution. The usefulness of G-CSF in drug-induced agranulocytosis has been investigated in the past, but with mixed results depending on the severity of the agranulocytosis.8,9 The review of 980 patients with drug-induced agranulocytosis did not show a significant association between decreased case-fatality rates and G-CSF, but did find a significant association between shorter duration of neutropenia and G-CSF.4 In our patient, who had severe agranulocytosis, the initial dose of G-CSF did not improve her ANC, but after the dose was increased, her ANC rapidly improved. However, this increase in ANC may have been seen in several days regardless of G-CSF dose escalation given that it has been shown that G-CSF causes neutrophil counts to recover in 6 to 12 days.10 Thus, there appears to be a role for using G-CSF in patients with agranulocytosis, regardless of the severity, although it may take additional doses and several days to resolve the neutropenia in patients with severe agranulocytosis.

Regarding possibly rechallenging patients with the offending drug, there have been several published reports of patients being rechallenged with a drug that was suspected of causing neutropenia and subsequently experiencing neutropenia again.11,12 Whitman et al13 described a case of cefazolin-induced leukopenia in a patient who then experienced leukopenia again when given cefoxitin. They concluded that b-lactam antibiotics should be avoided if leukopenia caused by these drugs is suspected. However, Uy et al5 described a case of ceftriaxone-induced neutropenia with improvement in the neutrophil count despite the patient being started on a cefepime regimen. We would recommend that our patient avoid future use of ceftriaxone. She will also probably need close monitoring should she require other b-lactam antibiotics.

18 190

18 190a

CONCLUSION

We present a case of idiosyncratic drug-induced agranulocytosis attributed to ceftriaxone. Although ceftriaxone is frequently used in both the inpatient and outpatient setting, serious adverse effects, such as this one, must be monitored for, especially in patients who are receiving prolonged therapy or high doses. Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and G-CSF should be administered, with daily ANC monitoring.

Disclosure Statement

The author(s) have no conflicts of interest to disclose.

Acknowledgments

Kathleen Louden, ELS, of Louden Health Communications performed a primary copy edit.

How to Cite this Article

Genchanok Y, Tolu SS, Wang H, Arora S. Agranulocytosis from outpatient antimicrobial treatment with ceftriaxone: A case report. Perm J 2019;23:18-190. DOI: https://doi.org/10.7812/TPP/18-190

Author Affiliations

1 Division of Hospital Medicine, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

2 Albert Einstein College of Medicine, Bronx, NY

Corresponding Author

Yevgeniy Genchanok, MD (ygenchan@montefiore.org)

References
1. Tice AD, Rehm SJ, Dalovisio JR, et al; IDSA. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004 Jun 15;38(12):1651-72. DOI: https://doi.org/10.1086/420939.
 2. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug;30(2):239-45. DOI: https://doi.org/10.1038/clpt.1981.154.
 3. Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008 Jan;15(1):15-21. DOI: https://doi.org/10.1097/MOH.0b013e3282f15fb9.
 4. Andersohn F, Konzen C, Garbe E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007 May 1;146(9):657-65. DOI: https://doi.org/10.7326/0003-4819-146-9-200705010-00009.
 5. Uy N, Thiagarajan P, Musher DM. Cephalosporin side chain idiosyncrasies: A case report of ceftriaxone-induced agranulocytosis and review of literature. Open Forum Infect Dis 2015 Feb 14;2(1):ofv007. DOI: https://doi.org/10.1093/ofid/ofv007.
 6. Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: An update of its use in the management of community-acquired and nosocomial infections. Drugs 2002 May;62(7):1041-89. DOI: https://doi.org/10.2165/00003495-200262070-00005.
 7. Duncan CJ, Evans TJ, Seaton RA. Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2010 Nov;65(11):2483-4. DOI: https://doi.org/10.1093/jac/dkq339.
 8. Tajiri J, Noguchi S, Okamura S, et al. Granulocyte colony-stimulating factor treatment of antithyroid drug-induced granulocytopenia. Arch Intern Med 1993 Feb 22;153(4):509-14. DOI: https://doi.org/10.1001/archinte.1993.00410040073011.
 9. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: A prospective study. Thyroid 1999 Jan;9(1):29-31. DOI: https://doi.org/10.1089/thy.1999.9.29.
 10. Wickramanayake PD, Scheid C, Josting A, Katay I, Schulz A, Diehl V. Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis. Eur J Med Res 1995 Dec 18;1(3):153-6.
 11. Duff JM, Moreb JS, Muwalla F. Severe neutropenia following a prolonged course of vancomycin that progressed to agranulocytosis with drug reexposure. Ann Pharmacother 2012 Jan;46(1):e1. DOI: https://doi.org/10.1345/aph.1Q467.
 12. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006 Mar;188(3):255-63. DOI: https://doi.org/10.1192/bjp.188.3.255.
 13. Whitman CB, Joseph JM, Sjoholm LO. Cephalosporin-induced leukopenia following rechallenge with cefoxitin. Ann Pharmacother 2008 Sep;42(9):1327-32. DOI: https://doi.org/10.1345/aph.1L183.

Keywords: agranulocytosis, antimicrobial treatment with ceftriaxone, ceftriaxone therapy, idiosyncratic drug-induced agranulocytosis

Reprint Permissions

The Permanente Journal welcomes requests for reprints and reproduction. Use of any and all published materials is copyrighted and protected.

SUBSCRIPTION

Journal subscriptions for The Permanente Journal are entered for the calendar year. Advance payment in US dollars is required.

CIRCULATION

27,000 print readers per quarter, 15,350 eTOC readers, and in 2018, 2 million page views of TPJ articles in PubMed from a broad international readership.

Indexing

Indexed in MEDLINE, PubMed Central, HINARI, EMBASE, EBSCO Academic Search Complete, rdrb, CrossRef, and SciVerse/Scopus.


Click here to join the eTOC subscription list or text TPJ to 22828. You will receive an Email notice with the Table of Contents of The Permanente Journal.


                                             

 

 

ISSN 1552-5767 Copyright © 2019 thepermanentejournal.org.

All Rights Reserved.